Singapore markets closed

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.7900-0.0300 (-1.65%)
At close: 04:00PM EST
1.7900 0.00 (0.00%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.8200
Open1.8100
Bid1.7700 x 2200
Ask1.7900 x 1400
Day's range1.7700 - 1.8400
52-week range1.4500 - 6.3200
Volume1,213,767
Avg. volume1,479,988
Market cap296.916M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.3990
Earnings date10 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.58
  • Business Wire

    Women in Psychedelics Announces atai as Platinum Sponsors

    TORONTO, November 04, 2022--The Women in Psychedelics Network ("WIPN" or "Network"), a network of professionals from all corners of the psychedelic industry strengthening women’s voices and providing opportunities to move mental health solutions forward, today announced atai Life Sciences N.V. (NASDAQ: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, as a platinum sponsor of the Network, through its philanthropic arm atai Im

  • Motley Fool

    New Regulations for Psychedelics? Here's What Investors Need to Know

    If you love investing in businesses that are on the bleeding edge of biotechnology, psychedelics companies are right up your alley. Despite substantial cultural baggage and significant legal hurdles, psychedelic medicines are proving themselves to be highly effective at treating mental illnesses like depression and post-traumatic stress disorder (PTSD), and that means they're likely to be quite lucrative for the developers. On July 13, the Drug Enforcement Agency (DEA) said it was scheduling a public hearing for Aug. 22, so people would have a chance to comment on a proposed rule that would move five psychedelic compounds into the Schedule 1 category.